Clinical trial

Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)

NCT03043872

Study summary

ClinicalTrials.gov

Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)

Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE3

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

5 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Durvalumab Normalized identity: durvalumab View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Tremelimumab Normalized identity: tremelimumab View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Carboplatin Normalized identity: carboplatin View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Cisplatin Normalized identity: cisplatin View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Etoposide Normalized identity: etoposide View linked drug · Find medicine records · Find other trials using this name

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2017-03-27

PhasePHASE3

Conditions

Small Cell Lung Carcinoma Extensive Diseaseunresolved

Interventions

DurvalumabDRUG · verified · RxNorm: durvalumab

TremelimumabDRUG · verified · RxNorm: tremelimumab

CarboplatinDRUG · verified · RxNorm: carboplatin

CisplatinDRUG · verified · RxNorm: cisplatin

EtoposideDRUG · verified · RxNorm: etoposide

Sponsors & collaborators

AstraZenecalead sponsor

Mapped research locations

BudapestHungary4 Saint PetersburgRussia4 SofiaBulgaria4 MadridSpain3 BeijingChina3 PragueCzechia3 HangzhouChina3 SeoulSouth Korea2 TaipeiTaiwan2 ShanghaiChina2 ViennaAustria2 TaichungTaiwan2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03043872 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.